Dactinomycin (A) and vincristine (V) with or without cyclophosphamide (C) and radiation therapy (RT) for newly diagnosed patients with low-risk embryonal/botryoid rhabdomyosarcoma (RMS). An IRS-V report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group (STS COG)
Reviewer: Charles Wood, MD
Abramson Cancer Center of the University of Pennsylvania
Last Modified: June 4, 2006
Presenter: Walterhouse JL et al.
Presenter's Affiliation: Children's Hospital of Los Angeles, Los Angeles, CA
Type of Session: Scientific
- The IRS-III and –IV studies defined 3 risk groups of rhabdomyosarcoma patients: low-risk (35%), intermediate-risk (50%), and high-risk (15%)
- Low-risk patients have favorable histology, and have localized tumor at a favorable site, or tumor at an unfavorable site that has been grossly resected prior to initiation of chemotherapy
- Low-risk patients were found to have a 5-year failure-free survival (FFS) of 83% and an overall survival (OS) of 95% on IRS-III and –IV
Materials and Methods
- 2 subgroups of patients were identified for the IRS-V low-risk RMS study (D9602) (1997 – 2004) per the hypothesis that different treatment intensities were required to achieve similar outcomes
- Subgroup A patients had Stage 1/Group I/IIA, Stage 1/Group III/orbit, or Stage 2/Group I disease and received VA with or without local RT (for residual tumor after surgery and beginning at approximately week 3 of chemotherapy)
- Subgroup B patients had Stage 1/Group IIB/C, Stage 2/Group II, Stage 1/Group III/non-orbit, or Stage 3/Group I/II disease and received VAC with or without local RT (for residual tumor after surgery and beginning at approximately week 3 of chemotherapy)
- Radiation doses were decreased versus IRS-IV for node-negative Group II patients (36 Gy versus 41.4 Gy) and Group III orbit patients (45 Gy versus 50.4/59.4 Gy)
- Eligibility requirements included patients < 50 years, no history of previous treatment, and with central pathologic confirmation of disease
- The primary end-point was FFS
- Median follow-up was 2.9 years
- Estimated 3-year FFS was 89% for Subgroup A patients and 89% for Subgroup B patients
- Estimated 3-year FFS was 80% for Stage 1/Group IIA patients and 88% for Group III orbit disease
- There is no evidence to suggest differences in outcome for patients treated on D9602 versus similar patients treated on IRS-III and –IV
- An estimated 3-year FFS of > 85% may be achieved in patients with characteristics such as those in Subgroup A who are treated with VA or in patients with characteristics such as those in Subgroup B who are treated with VAC
- Additionally, a similar FFS may be achieved in Subgroup A patients with Group III disease involving the orbit and who are treated with VA and 45 Gy RT
- Modifying treatment intensity according to pre-defined patient disease characteristics may be of value in maintaining excellent FFS and OS rates in low-risk RMS patients
Soft Tissue Sarcoma Therapy Limb Salvage Rate 81 Percent
Sep 22, 2011 - Tumor necrosis factor-α and melphalan-based isolated limb perfusion therapy has a limb salvage rate of 81 percent in patients with locally advanced extremity soft tissue sarcomas who would have otherwise undergone amputation, according to a study published online Sept. 19 in the Journal of Clinical Oncology.
Frequently Asked Questions
National Cancer Institute
I Wish You Knew
How cancer patients have changed my life
Blogs and Web Chats
OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.
Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!